Satellite Symposium

Decision-making in Superficial Venous Disease Treatment: The Roles of Data, Device, and Patient Voice

Friday, October 14, 2022

1:15 PM – 2:15 PM US CDT

Location: Hyatt Regency, Empire C

Industry Program Chair(s)

Daniel J. Denmark, PhD

Scientific Communications Program Specialist
Medtronic
Plymouth, Minnesota

Disclosure: Medtronic (Individual(s) Involved: Self; Products/Services: VenaSeal and ClosureFast - Evidence Dissemination): Employment

Industry Speaker(s)

Ramona Gupta, MD, FSIR

Speaker
Northwestern University
Northwestern University
Chicago, Illinois

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Antonios Gasparis, MD

Professor of Surgery
Stony Brook Medicine
Dix Hills, New York

Disclosure: TACTILE MEDICAL (Individual(s) Involved: Self; Products/Services: Flexitouch, Entre): Consultant/Advisory Board
Misaki Kiguchi, MD, MBA, FACS

Vascular Surgeon
MedStar Georgetown University Hospital Washington, DC
Washington, District of Columbia

Disclosure: Boston Scientific (Individual(s) Involved: Self; Products/Services: Varithena): Speaker/Honoraria; Medtronic Inc. (Individual(s) Involved: Self; Products/Services: ClosureFast, VenaSeal): Speaker/Honoraria

This program explores the patient's journey through chronic venous insufficiency: from symptom onset, through treatment, and on to follow up. Special attention is given to the patient's voice and emphasis on whether they are satisfied with different aspects of their treatment. In addition to a case-driven discussion, there will also be a review of current patient reported outcome measures and consideration of what they will look like in the future.

Learning Objectives:

Formulate a chronic venous insufficiency treatment plan based not only on duplex ultrasound and other conventional medical assessments, but also on the quality of life factors that are most important to the patient.
Discriminate between state-of-the-art chronic venous insufficiency treatment modalities, namely endothermal ablation and cyanoacrylate closure.
Recognize the capabilities and limitations of patient reported outcome measures, especially for assessing peri-procedural patient treatment satisfaction.